FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 01:12:52 08/06/2024 am IST | ||
| 9.82 EUR | +2.29% |
|
| Current month | +3.37% | ||
| 1 month | +9.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 9.82 | +2.29% |
| 06/24/06 | 9.6 | +7.62% |
| 05/24/05 | 8.92 | -7.76% |
| 04/24/04 | 9.67 | +1.47% |
| 03/24/03 | 9.53 | +0.32% |
Real-time Boerse Frankfurt Warrants
Last update June 08, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9NAS |
| ISIN | DE000SW9NAS7 |
| Date issued | 29/04/2024 |
| Strike | 1,916 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.16 € |
|---|---|
| Lowest since issue | 8.11 € |
| Spread | 0.28 € |
| Spread % | 2.77% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.67%
- Stock Market
- Certificates
- Certificat
